CGRP antagonists: unravelling the role of CGRP in migraine

Migraine is a complex, debilitating neurovascular disorder. Although knowledge on the main molecular players is still incomplete, recent preclinical and clinical findings indicate that there is a clear correlation between migraine-associated headache and the release of the neuropeptide calcitonin ge...

Full description

Saved in:
Bibliographic Details
Published in:Trends in pharmacological sciences (Regular ed.) 2007-11, Vol.28 (11), p.580-587
Main Authors: Doods, Henri, Arndt, Kirsten, Rudolf, Klaus, Just, Stefan
Format: Article
Language:English
Subjects:
Advanced Basic Science
Animals
Azepines - chemistry
Azepines - pharmacology
Azepines - therapeutic use
Calcitonin Gene-Related Peptide - antagonists & inhibitors
Calcitonin Gene-Related Peptide - physiology
Clinical Trials as Topic
Dipeptides - chemistry
Dipeptides - pharmacology
Dipeptides - therapeutic use
Humans
Imidazoles - chemistry
Imidazoles - pharmacology
Imidazoles - therapeutic use
Migraine Disorders - drug therapy
Migraine Disorders - physiopathology
Models, Biological
Molecular Structure
Quinazolines - chemistry
Quinazolines - pharmacology
Quinazolines - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Migraine is a complex, debilitating neurovascular disorder. Although knowledge on the main molecular players is still incomplete, recent preclinical and clinical findings indicate that there is a clear correlation between migraine-associated headache and the release of the neuropeptide calcitonin gene-related peptide (CGRP). BIBN4096 was the first CGRP antagonist to be tested in clinical trials for the treatment of migraine. The proven efficacy of this agent, and also the CGRP antagonist MK-0974, to alleviate acute migraine headache provided significant support for the hypothesis that CGRP has an important role in migraine pathophysiology. Moreover, the recently published results from Phase II trials are encouraging and suggest that this new type of drug might offer advantages over existing therapies for patients suffering from migraine and related headaches.
ISSN:0165-6147
1873-3735
DOI:10.1016/j.tips.2007.10.005